

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

09 Jun 2026

### The effect of letrozole with misoprostol on induced abortion in the second trimester

#### Protocol summary

##### Study aim

The effect of letrozole with misoprostol on induced abortion in the second trimester

##### Design

Study Design : Randomized ; Target population: Pregnant women with under 13 weeks nonviable pregnancy. Inclusion criteria : pregnancy with under 13 weeks nonviable fetus .Exclusion criteria : any condition requiring emergency intervention .76 participants were randomized into two groups.control group use Misoprostol for abortion and intervention group will receive Letrozole plus Misoprostol .

##### Settings and conduct

76 consecutive pregnant women with gestational age of 13-26 weeks who were candidate for stopping pregnancy due to fetal reasons who come to Tabriz,Alzahra hospital.76 participants were randomized into two groups. Control group use Misoprostol for abortion (gold standard treatment) and intervention group will receive Letrozole plus Misoprostol .

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Gestational age of 13 to 26 with an indication for termination of pregnancy in medical method; Reason for termination of pregnancy, such as missed abortion; Pregnancy NULL; Therapeutic abortion legal authorization and consent of patients Exclusion criteria:Pain and bleeding; Drug sensitivity to misoprostol; history of corticosteroid use

##### Intervention groups

Intervention group: 7.5 mg , letrozole (Manufacturing Iran Hormones Company) prescribed up to three doses at home, the patient was hospitalized on the fourth and Misoprostol 400 micrograms (made by SEARLE UK) is administered sublingually every 3 hours to a maximum of 5 doses. Control group: The group received placebo for 4 days (Folic acid as blind-made by IRAN DARO) and then misoprostol according to the ACOG protocol.

##### Main outcome variables

Primary out come is rate of complete abortion and

Secondary outcomes are rate and duration of bleeding and other side effects such as nausea , vomiting , diarrhea , dizziness , headache.

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20130626013777N2**

Registration date: **2019-02-14, 1397/11/25**

Registration timing: **registered\_while\_recruiting**

Last update: **2019-02-14, 1397/11/25**

Update count: **0**

##### Registration date

2019-02-14, 1397/11/25

##### Registrant information

##### Name

Shamsi Abbasalizadeh

##### Name of organization / entity

Tabriz University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 41 1553 9161

##### Email address

abbasalizadehs@tbzmed.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-02-13, 1397/11/24

##### Expected recruitment end date

2020-02-13, 1398/11/24

##### Actual recruitment start date

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

The effect of letrozole with misoprostol on induced abortion in the second trimester

**Public title**

Comparison the effect of Letrozole with Misoprostol on induction of second trimester abortion in pregnancy

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

patients more than 18 years of age Gestational age of 13 to 26 with an indication for termination of pregnancy in medical method Hb above 10 Reason for termination of pregnancy, such as missed abortion; Pregnancy NULL; Therapeutic abortion legal authorization and consent of patients BMI between 25-25

**Exclusion criteria:**

Pain and bleeding Drug sensitivity to misoprostol; Severe anemia Coagulopathy or taking anticoagulants Active liver disease Cardiovascular disease and uncontrolled seizures Adrenal disease history of corticosteroid use

**Age**

From **18 years** old

**Gender**

Female

**Phase**

2

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **86**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Patients were randomly assigned to two groups of 38 A (receiving Letrozole and Misoprostol) and B (Misoprostol) by using the random numbers table.

**Blinding (investigator's opinion)**

Not blinded

**Blinding description****Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee**

**Name of ethics committee**

Ethics Committee Of Tabriz University Of Medical Sciences

**Street address**

Third Floor, Central Building of Number2, Golgasht Street

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5166616471

**Approval date**

2019-01-21, 1397/11/01

**Ethics committee reference number**

IR.TBZMED.REC.1397.855

**Health conditions studied****1****Description of health condition studied**

Termination of pregnancy in the second trimester

**ICD-10 code**

O04

**ICD-10 code description**

Medical abortion

**Primary outcomes****1****Description**

abortion

**Timepoint**

The start of the intervention up to 24

**Method of measurement**

Ultrasound

**2****Description**

Time between medication abortion

**Timepoint**

The start of the intervention up to 24

**Method of measurement**

hour

**3****Description**

The need for curettage

**Timepoint**

Seven days after abortion

**Method of measurement**

Clinical

**Secondary outcomes****1****Description**

Side effects

## Timepoint

Intervention to 24 hours after administration

## Method of measurement

Clinical

## Intervention groups

### 1

#### Description

Intervention group: 7.5 mg , letrozole (Manufacturing Iran Hormones Company) prescribed up to three doses at home, the patient was hospitalized on the fourth and Misoprostol 400 micrograms (made by SEARLE UK) is administered sublingually every 3 hours to a maximum of 5 doses.

#### Category

Treatment - Drugs

### 2

#### Description

Control group: The group received placebo for 4 days (Folic acid as blind-made by IRAN DARO) and then misoprostol according to the ACOG protocol.

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Alzahra Hospital

##### Full name of responsible person

Shamsi Abbasalizadeh

##### Street address

Alzahra Hospital, South Artesh St.

##### City

Tabriz

##### Province

East Azarbaijan

##### Postal code

5138665793

##### Phone

+98 41 3553 9161

##### Email

lahroudin@gmail.com

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

معاونت تحقیقات و فناوری دانشگاه علوم پزشکی تبریز

##### Full name of responsible person

Abolghasem Juiban

##### Street address

Third Floor, Central Building of Number2, Golgasht Street

## City

Tabriz

## Province

East Azarbaijan

## Postal code

5138665793

## Phone

+98 41 3553 9161

## Email

lahroudin@gmail.com

## Grant name

## Grant code / Reference number

## Is the source of funding the same sponsor organization/entity?

Yes

## Title of funding source

معاونت تحقیقات و فناوری دانشگاه علوم پزشکی تبریز

## Proportion provided by this source

100

## Public or private sector

Public

## Domestic or foreign origin

Domestic

## Category of foreign source of funding

empty

## Country of origin

## Type of organization providing the funding

Academic

## Person responsible for general inquiries

### Contact

#### Name of organization / entity

Tabriz University of Medical Sciences

#### Full name of responsible person

Shamsi Abbasalizadeh

#### Position

Associate Professor

#### Latest degree

Subspecialist

#### Other areas of specialty/work

Gynecology and Obstetrics

#### Street address

Azadi Avenue, Golgashte St, Tabriz University of Medical Sciences

#### City

Tabriz

#### Province

East Azarbaijan

#### Postal code

5138665793

#### Phone

+98 41 3553 9161

#### Email

lahroudin@gmail.com

## Person responsible for scientific inquiries

### Contact

#### Name of organization / entity

Tabriz University of Medical Sciences

**Full name of responsible person**

Shamsi Abbasalizadeh

**Position**

Associate Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

Azadi Avenue, Golgashte St, Tabriz University of Medical Sciences

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5138665793

**Phone**

+98 41 3553 9161

**Email**

lahroudin@gmail.com

Azadi Avenue, Golgashte St, Tabriz University of Medical Sciences

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5138665793

**Phone**

+98 41 3553 9161

**Email**

lahroudin@gmail.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available

**Person responsible for updating data****Contact****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Shamsi Abbasalizadeh

**Position**

Associate Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**